A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK

References

• Dewey RB Jr. Management of motor complications in Parkinson's disease. Neurology 2004;62:S3-7
   PubMedGoogle Scholar
• Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002;17:60-7
   Google Scholar
• Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-13
   PubMed Web of Science ®Google Scholar
• Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003;9:163-8
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-18
   PubMed Web of Science ®Google Scholar
• Carter JH, Stewart BJ, Archbold PG, et al. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Mov Disord 1998;13:20-8
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, ito-Leon J, Alonso F, et al. Quality of life of caregivers in Parkinson's disease. Qual Life Res 2005;14:436-72
   Google Scholar
• Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson's disease. Mov Disord 2007;22:924-31
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Arroyo S, Rojo-Abuin JM, et al. Burden, perceived health status, and mood among caregivers of Parkinson's disease patients. Mov Disord 2008;23:1673-80
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians, 2006. Report No.: CG35
   Google Scholar
• Department of Health & Human Services. Levodopa/carbidopa as orphan drug, application #99-1294, 2000
   Google Scholar
• European Commission – Enterprise and Industry Directorate General – Consumer goods – Pharmaceuticals. Levodopa and Carbidopa (Gastroenteral use) EU Orphan Designation number: EU3/01/035. 2008. Available http://ec.europa.eu/health/documents/community-register/html/o035.htm (Last accessed 8 December 2011)
   Google Scholar
• Department of Health of Ageing Therapeutic Goods Administration (2006). Duodopa (levodopa 20 mg/mL and carbidopa 5 mg/mL) intestinal gel suspension – Orphan Drug Application, Submission No. 2006/0636/1. 2006
   Google Scholar
• Department of Health, Labor and Welfare. Designation number 224. 2009
   Google Scholar
• European Commission. The Orphan Drugs Strategy. 2007
   Google Scholar
• Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42
   PubMed Web of Science ®Google Scholar
• Frankel J. Verification of epidemiological and clinical assumptions for Duodopa Budget Impact Model. 2006 (personal communication)
   Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community based study. Brain 2000;123:2297-305
   PubMed Web of Science ®Google Scholar
• Findley L, Wood E, Lowin J, et al. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 2011;14:130-9
   PubMedGoogle Scholar
• Willis M, Persson U, Zoellner Y, et al. Reducing uncertainty in value-based pricing using evidence development agreements. The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden. Applied Health Economics & Health Policy 2010;8:1-10
   PubMedGoogle Scholar
• Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001;4:308-15
   PubMedGoogle Scholar
• Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. Qual Life Res 2000;9:819-27
   PubMed Web of Science ®Google Scholar
• Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002;20:617-28
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Neville A, Parson R, Nyhom D. Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. Submitted 2011
   Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease – long-term experience. Acta Neurol Scand 2001;104:343-8
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
   PubMed Web of Science ®Google Scholar
• Nyholm D, Remahl N, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson's disease. Neurology. 2005 Jan 25;64(2):216-23
   Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin 2008 Nov;24(11):3063-72
   PubMedGoogle Scholar
• Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-91
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Appraising Orphan Drugs (Draft 3). Available at: http://www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf [Last accessed 13 December 2010]
   Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005;331:1016-19
   PubMed Web of Science ®Google Scholar
• Department of Health. NHS Reference Costs Appendix NSRC04 NHS Trust and PCT Combined Reference Cost Schedules. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098945 (Last accessed 13 December 2010)
   Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
   PubMed Web of Science ®Google Scholar
• Curtis L. Unit Costs of Health and Social Care. Personal Social Services Research Unit, University of Kent. 2008. Available at: http://www.pssru.ac.uk/uc/uc2008contents.htm (Last accessed 15 December 2010)
   Google Scholar
• Joint Formulary Committee. British National Formulary [57]. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009
   Google Scholar